A brand new antibody therapy for COVID-19 can be rolled out to NHS sufferers throughout the UK from subsequent week, the federal government has introduced.
Ronapreve, an antibody cocktail, can be initially offered to hospital sufferers with COVID-19 who’re over the age of fifty or aged 12 to 49 and are thought of to be immunocompromised.
This consists of folks with some kinds of most cancers or autoimmune ailments.
The drug has been proven to cut back hospital stays by 4 days and the chance of demise by a fifth.
The federal government stated it has secured sufficient provide of the brand new therapeutic therapy for NHS sufferers throughout the 4 nations, with plans to start treating eligible hospital sufferers from subsequent week.
Antibody testing can be used to find out whether or not sufferers are seronegative, that means they don’t have an ample present antibody response and will due to this fact profit from the medication.
Ronapreve is the primary antibody therapy for COVID-19 to be permitted by the Medicines and Healthcare merchandise Regulatory Company (MHRA) to be used within the UK.
Well being Secretary Sajid Javid stated: “We have now secured a model new therapy for our most susceptible sufferers in hospitals throughout the UK and I’m thrilled it is going to be saving lives from as early as subsequent week.
“The UK is main the world in figuring out and rolling out life-saving medicines, significantly for COVID-19, and we are going to proceed our important work to search out the very best therapies accessible to save lots of lives and shield the NHS.”